Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 25.04

+2.6%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B.REVERE who wrote (381)	6/22/1998 1:53:00 PM
From: Anthony Wong	Read Replies (1) of 1722

The pharmaceutical analyst from Hambrest and Quist was interviewed on CNBC by Sue Herera around half an hour ago. He was still bullish on the drug group - few Asian exposure, good defensive play etc, though the group was quite expensive. Particularly liked Merck and Johnson & Johnson. On PDA's non approval letter on Zeldox. He had no further information as to details. Thought FDA was walking on egg shells after the incidents of drugs such as WLA's Rezulin and today's AHP's withdrwal of Duract. He thought Zeldox's approval might be delayed to next summer, but that it won't hurt Pfizer, what with Viagra being approved later this year in Europe and their strong drug pipeline. He still thinks Pfizer is a buy.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next